Results 181 to 190 of about 2,795,577 (349)

Emerging strategies to target metastasis and therapy resistance in melanoma

open access: yesMolecular Oncology, EarlyView.
Emerging studies propose new approaches to interfere with melanoma progression. In recognition of melanoma awareness month, at Molecular Oncology, we highlight recently published research articles, focusing on novel therapeutic targets driving metastatic spread and outlining different strategies to overcome resistance to BRAF inhibitors and anti‐PD‐1 ...
Amel Aziba
wiley   +1 more source

SOCS3 Genetic Polymorphism Is Associated With Clinical Features and Prognosis of Hepatocellular Carcinoma Patients Receiving Hepatectomy

open access: gold, 2015
Bei‐Ge Jiang   +9 more
openalex   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

open access: yesFEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold   +11 more
wiley   +1 more source

Differential regulation of ZFAS1 splice variants by endoplasmic reticulum stress in hepatocyte cell lines

open access: yesFEBS Open Bio, EarlyView.
ZFAS1 is a lncRNA promoting cell proliferation and migration, exhibiting high expression in various cancers. It is conserved, widely expressed, and produces multiple splice variants with unclear roles. We identified several splice variants in hepatocyte models, and found that inhibiting or suppressing regulators of the unfolded protein response (PERK ...
Sébastien Soubeyrand   +2 more
wiley   +1 more source

Tuber yield prognosis model and agronomic nitrogen use efficiency of potato cultivars

open access: bronze, 2016
Paulo Cézar Rezende Fontes   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy